尿毒症患者采用左卡尼汀配合血液透析治疗的临床效果评价

Evaluation on the clinical effect of levocarnitine on the basis of hemodialysis in patients suffering from uremia

目的探讨尿毒症患者在血液透析治疗基础上加用左卡尼汀的临床效果。方法60例尿毒症患者,随机分为对照组和观察组,每组30例。对照组应用常规血液透析治疗,观察组在对照组治疗基础上加用左卡尼汀治疗。比较两组治疗效果及治疗前后炎性因子[白细胞介素-4(IL-4)、白细胞介素-10(IL-10)]、血液及营养指标(血清蛋白、血红蛋白、血清总蛋白、红细胞比容)、肾功能指标[尿素氮(BUN)、肌酐(Scr)]水平。结果观察组治疗总有效率为96.67%,高于对照组的80.00%,差异具有统计学意义(P<0.05)。治疗后,观察组IL-4、IL-10水平分别为(33.72±15.08)、(14.73±6.34)ng/L,低于对照组的(45.72±15.37)、(22.22±7.30)ng/L,差异具有统计学意义(P<0.05)。治疗后,观察组血清蛋白、血红蛋白、血清总蛋白、红细胞比容水平分别为(42.74±3.93)g/L、(99.82±11.42)g/L、(70.78±4.23)g/L、(33.72±6.79)%,高于对照组的(36.57±3.42)g/L、(63.42±11.73)g/L、(61.22±3.92)g/L、(20.73±4.19)%,差异具有统计学意义(P<0.05)。治疗后,观察组BUN、Scr水平分别为(10.01±1.52)、(0.52±0.13)mmol/L,低于对照组的(16.40±0.97)、(1.02±0.29)mmol/L,差异具有统计学意义(P<0.05)。结论尿毒症患者在血液透析治疗基础上加用左卡尼汀,可提高治疗效果,降低炎性反应,改善贫血、营养不良状态及肾功能,值得推广应用。

Objective To discuss the clinical effect of levocarnitine on the basis of hemodialysis in patients suffering from uremia.Methods A total of 60 cases of uremia patients were randomly divided into control group and observation group,with 30 cases in each group.The control group was treated with conventional hemodialysis,and the observation group was treated with levocarnitine on the basis of the treatment of the control group.Both groups were compared in terms of therapeutic effect,inflammatory factors[interleukin-4(IL-4),interleukin-10(IL-10)],blood and nutritional indicators(serum protein,hemoglobin,serum total protein,hematocrit),renal function indicators[blood urea nitrogen(BUN),serum creatinine(Scr)]levels before and after treatment.Results The total effective rate of the observation group was 96.67%,which was higher than 80.00%of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of IL-4 and IL-10 in the observation group were(33.72±15.08)and(14.73±6.34)ng/L,which were lower than(45.72±15.37)and(22.22±7.30)ng/L in the control group,and the differences were all statistically significant(P<0.05).After treatment,the levels of serum protein,hemoglobin,total serum protein and hematocrit in the observation group were(42.74±3.93)g/L,(99.82±11.42)g/L,(70.78±4.23)g/L,and(33.72±6.79)%,which were higher than(36.57±3.42)g/L,(63.42±11.73)g/L,(61.22±3.92)g/L,and(20.73±4.19)%in the control group,and the differences were all statistically significant(P<0.05).After treatment,the levels of BUN and Scr in the observation group were(10.01±1.52)and(0.52±0.13)mmol/L,which were lower than(16.40±0.97)and(1.02±0.29)mmol/L in the control group,and the differences were all statistically significant(P<0.05).Conclusion The addition of levocarnitine on the basis of hemodialysis to patients suffering from uremia can improve the therapeutic effect,reduce the inflammatory response,and improve anemia,malnutrition and renal function of patients,which is worthy of promotion and application.